

# Yasuo Miyoshi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1693959/publications.pdf>

Version: 2024-02-01

140  
papers

5,192  
citations

94433

37  
h-index

98798

67  
g-index

143  
all docs

143  
docs citations

143  
times ranked

7508  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of serum adiponectin levels with breast cancer risk. <i>Clinical Cancer Research</i> , 2003, 9, 5699-704.	7.0	317
2	Down-Regulation of <i>LATS1</i> and <i>LATS2</i> mRNA Expression by Promoter Hypermethylation and Its Association with Biologically Aggressive Phenotype in Human Breast Cancers. <i>Clinical Cancer Research</i> , 2005, 11, 1380-1385.	7.0	278
3	Prediction of Docetaxel Response in Human Breast Cancer by Gene Expression Profiling. <i>Journal of Clinical Oncology</i> , 2005, 23, 422-431.	1.6	263
4	Association of centrosomal kinase <i>STK15/BTAK</i> mRNA expression with chromosomal instability in human breast cancers. <i>International Journal of Cancer</i> , 2001, 92, 370-373.	5.1	214
5	High Thioredoxin Expression Is Associated with Resistance to Docetaxel in Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 8425-8430.	7.0	162
6	High expression of leptin receptor mRNA in breast cancer tissue predicts poor prognosis for patients with high, but not low, serum leptin levels. <i>International Journal of Cancer</i> , 2006, 118, 1414-1419.	5.1	157
7	Clinicopathologic Analysis of Breast Cancers with <i>PIK3CA</i> Mutations in Japanese Women. <i>Clinical Cancer Research</i> , 2007, 13, 408-414.	7.0	138
8	Mechanism of resistance to endocrine therapy in breast cancer: the important role of <i>PI3K/Akt/mTOR</i> in estrogen receptor-positive, <i>HER2</i> -negative breast cancer. <i>Breast Cancer</i> , 2018, 25, 392-401.	2.9	134
9	Involvement of up-regulation of 17 $\beta$ -hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. <i>International Journal of Cancer</i> , 2001, 94, 685-689.	5.1	132
10	Quantitative analysis of estrogen receptor- $\alpha$ mRNA and its variants in human breast cancers. <i>International Journal of Cancer</i> , 2000, 88, 733-736.	5.1	124
11	Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis. <i>International Journal of Oncology</i> , 2013, 42, 478-506.	3.3	104
12	Cosmetic outcome and patient satisfaction after skin-sparing mastectomy for breast cancer with immediate reconstruction of the breast. <i>Surgery</i> , 2008, 143, 414-425.	1.9	96
13	Prediction of response to docetaxel by <i>CYP3A4</i> mRNA expression in breast cancer tissues. <i>International Journal of Cancer</i> , 2002, 97, 129-132.	5.1	93
14	Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. <i>Clinical Cancer Research</i> , 2003, 9, 2992-7.	7.0	86
15	High expression of ubiquitin carboxy-terminal hydrolase-L1 and -L3 mRNA predicts early recurrence in patients with invasive breast cancer. <i>Cancer Science</i> , 2006, 97, 523-529.	3.9	85
16	Growth-inhibitory effect of adiponectin via adiponectin receptor 1 on human breast cancer cells through inhibition of S-phase entry without inducing apoptosis. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 405-410.	2.5	84
17	Interaction of <i>BARD1</i> and <i>HP1</i> Is Required for <i>BRCA1</i> Retention at Sites of DNA Damage. <i>Cancer Research</i> , 2015, 75, 1311-1321.	0.9	83
18	Preoperative Evaluation of Residual Tumor Extent by Three-Dimensional Magnetic Resonance Imaging in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Breast Journal</i> , 2006, 12, 130-137.	1.0	77

#	ARTICLE	IF	CITATIONS
19	Demonstration of Adiponectin Receptors 1 and 2 mRNA expression in human breast cancer cells. <i>Cancer Letters</i> , 2007, 250, 229-236.	7.2	77
20	Quantitative analysis of estrogen receptor- $\alpha$ and - $\beta$ messenger RNA expression in breast carcinoma by real-time polymerase chain reaction. <i>Cancer</i> , 2000, 89, 1732-1738.	4.1	72
21	Connexin26 expression is associated with lymphatic vessel invasion and poor prognosis in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 11-17.	2.5	72
22	Xanthohumol suppresses oestrogen-signalling in breast cancer through the inhibition of BIG3-PHB2 interactions. <i>Scientific Reports</i> , 2014, 4, 7355.	3.3	68
23	Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells. <i>Nature Communications</i> , 2013, 4, 2443.	12.8	63
24	Association between 18F-FDG uptake and molecular subtype of breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1371-1377.	6.4	62
25	Correlation of the SUVmax of FDG-PET and ADC values of diffusion-weighted MR imaging with pathologic prognostic factors in breast carcinoma. <i>European Journal of Radiology</i> , 2016, 85, 943-949.	2.6	61
26	Polymorphisms of estrogen synthesizing and metabolizing genes and breast cancer risk in Japanese women. <i>Biomedicine and Pharmacotherapy</i> , 2003, 57, 471-481.	5.6	58
27	Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. <i>Breast Cancer</i> , 2015, 22, 235-244.	2.9	58
28	Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. <i>International Journal of Cancer</i> , 2001, 95, 255-259.	5.1	57
29	Association of GSTP1 CpG Islands Hypermethylation with Poor Prognosis in Human Breast Cancers. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 169-176.	2.5	57
30	Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. <i>Cancer Letters</i> , 2004, 210, 197-203.	7.2	55
31	Prognostic Significance of CD55 Expression in Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 4780-4786.	7.0	55
32	Molecular classification of primary breast tumors possessing distinct prognostic properties. <i>Human Molecular Genetics</i> , 2002, 11, 199-206.	2.9	54
33	Mutational analysis of the class I $\beta$ -tubulin gene in human breast cancer. <i>International Journal of Cancer</i> , 2002, 101, 46-51.	5.1	49
34	Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers. <i>Breast Cancer</i> , 2005, 12, 11-15.	2.9	48
35	Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel. <i>Clinical Breast Cancer</i> , 2018, 18, 400-409.	2.4	44
36	HERC2 Facilitates BLM and WRN Helicase Complex Interaction with RPA to Suppress G-Quadruplex DNA. <i>Cancer Research</i> , 2018, 78, 6371-6385.	0.9	41

#	ARTICLE	IF	CITATIONS
37	High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin but not with treatment of physician's choice in the EMBRACE study. <i>Breast Cancer</i> , 2020, 27, 706-715.	2.9	41
38	Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 5603-5619.	8.2	39
39	Mechanisms of estrogen receptor- $\alpha$ upregulation in breast cancers. <i>Medical Molecular Morphology</i> , 2010, 43, 193-196.	1.0	36
40	Increased Expression of BRCA1 mRNA Predicts Favorable Response to Anthracycline-Containing Chemotherapy in Breast Cancers. <i>Breast Cancer Research and Treatment</i> , 2003, 78, 45-50.	2.5	35
41	Isolation and characterization of a novel human pancreas-specific gene, panpcin, that is down-regulated in pancreatic cancer cells. , 1998, 22, 179-185.		34
42	Prognostic value of FDG-PET and DWI in breast cancer. <i>Annals of Nuclear Medicine</i> , 2018, 32, 44-53.	2.2	34
43	Quantitative assessment of mammographic density and breast cancer risk for Japanese women. <i>Breast</i> , 2008, 17, 27-35.	2.2	33
44	High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 204-211.	2.4	33
45	Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel. <i>BMC Cancer</i> , 2018, 18, 982.	2.6	33
46	Basal-like subtype and BRCA1 dysfunction in breast cancers. <i>International Journal of Clinical Oncology</i> , 2008, 13, 395-400.	2.2	32
47	Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. <i>International Journal of Oncology</i> , 2016, 49, 471-478.	3.3	32
48	Prognostic significance of preoperative 18F-FDG PET/CT for breast cancer subtypes. <i>Breast</i> , 2016, 30, 5-12.	2.2	31
49	Connexin26 expression is associated with aggressive phenotype in human papillary and follicular thyroid cancers. <i>Cancer Letters</i> , 2008, 262, 248-256.	7.2	29
50			

#	ARTICLE	IF	CITATIONS
55	Quantitative analysis of estrogen receptor- $\alpha$ and - $\beta$ messenger RNA expression in human pancreatic cancers by real-time polymerase chain reaction. <i>Cancer Letters</i> , 2001, 170, 91-97.	7.2	26
56	Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis. <i>Clinical Cancer Research</i> , 2003, 9, 1376-80.	7.0	26
57	Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women. <i>Clinical Cancer Research</i> , 2003, 9, 2229-33.	7.0	26
58	Present and future role of FDG-PET/CT imaging in the management of breast cancer. <i>Japanese Journal of Radiology</i> , 2016, 34, 167-180.	2.4	25
59	Quantitative Analysis of BRCA1 and BRCA2 mRNA Expression in Sporadic Breast Carcinomas and Its Relationship with Clinicopathological Characteristics. <i>Japanese Journal of Cancer Research</i> , 2001, 92, 624-630.	1.7	24
60	High BRCA2 mRNA expression predicts poor prognosis in breast cancer patients. <i>International Journal of Cancer</i> , 2002, 98, 879-882.	5.1	23
61	Association of loss of BRCA1 expression with centrosome aberration in human breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 421-430.	2.5	23
62	Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST – multicenter study in Japan. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1661-1671.	6.4	23
63	Significant association between high serum CCL5 levels and better disease-free survival of patients with early breast cancer. <i>Cancer Science</i> , 2020, 111, 209-218.	3.9	23
64	Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine. <i>Scientific Reports</i> , 2019, 9, 1811.	3.3	22
65	Differentiation of Follicular Thyroid Adenoma from Carcinoma by Means of Gene Expression Profiling with Adapter-Tagged Competitive Polymerase Chain Reaction. <i>Oncology</i> , 2005, 69, 428-435.	1.9	21
66	Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers. <i>Breast Cancer</i> , 2019, 26, 738-747.	2.9	21
67	Preliminary study of AI-assisted diagnosis using FDG-PET/CT for axillary lymph node metastasis in patients with breast cancer. <i>EJNMMI Research</i> , 2021, 11, 10.	2.5	20
68	Quantitative analysis of aromatase, sulfatase and 17 $\beta$ -HSD1 mRNA expression in soft tissue metastases of breast cancer. <i>Cancer Letters</i> , 2006, 243, 23-31.	7.2	19
69	BIG3 Inhibits the Estrogen-Dependent Nuclear Translocation of PHB2 via Multiple Karyopherin-Alpha Proteins in Breast Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0127707.	2.5	19
70	Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers. <i>International Journal of Clinical Oncology</i> , 2016, 21, 254-261.	2.2	19
71	Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. <i>International Journal of Clinical Oncology</i> , 2016, 21, 262-269.	2.2	19
72	Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 501-509.	2.5	18

#	ARTICLE	IF	CITATIONS
73	Acceleration of chromosomal instability by loss of BRCA1 expression and p53 abnormality in sporadic breast cancers. <i>Cancer Letters</i> , 2000, 159, 211-216.	7.2	17
74	Potential of Reduction in Total Tumor Volume Measured with 3D-MRI as a Prognostic Factor for Locally-Advanced Breast Cancer Patients Treated with Primary Chemotherapy. <i>Breast Journal</i> , 2008, 14, 523-531.	1.0	17
75	Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes. <i>World Journal of Surgical Oncology</i> , 2018, 16, 26.	1.9	17
76	High Serum Levels of Interleukin-18 Are Associated With Worse Outcomes in Patients With Breast Cancer. <i>Anticancer Research</i> , 2019, 39, 5009-5018.	1.1	17
77	Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in 18F-FDG-PET/CT Imaging for Predicting Pathological Complete Response in Breast Cancers Treated with Preoperative Chemotherapy. <i>Annals of Surgical Oncology</i> , 2019, 26, 2175-2183.	1.5	16
78	Prognostic Significance of Neutrophil-to-lymphocyte Ratio in Luminal Breast Cancers With Low Levels of Tumour-infiltrating Lymphocytes. <i>Anticancer Research</i> , 2020, 40, 2871-2880.	1.1	16
79	Predictive factors for anthracycline-based chemotherapy for human breast cancer. <i>Breast Cancer</i> , 2010, 17, 103-109.	2.9	15
80	Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer. <i>Oncotarget</i> , 2020, 11, 86-98.	1.8	15
81	Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0. <i>Nagoya Journal of Medical Science</i> , 2018, 80, 183-197.	0.3	15
82	Association of CYP17 genetic polymorphism with intra-tumoral estradiol concentrations but not with CYP17 messenger RNA levels in breast cancer tissue. <i>Cancer Letters</i> , 2003, 195, 81-86.	7.2	14
83	Down-Regulation of Intratumoral Aromatase Messenger RNA Levels by Docetaxel in Human Breast Cancers. <i>Clinical Cancer Research</i> , 2004, 10, 8163-8169.	7.0	14
84	Influence of body mass index on clinicopathological factors including estrogen receptor, progesterone receptor, and Ki67 expression levels in breast cancers. <i>International Journal of Clinical Oncology</i> , 2014, 19, 467-472.	2.2	14
85	Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER+, and HER2 <sup>+</sup> Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 197-203.	2.4	14
86	HP1 regulates the localization of FANCD1 at sites of DNA double-strand breaks. <i>Cancer Science</i> , 2016, 107, 1406-1415.	3.9	14
87	Diagnostic and prognostic value of 18F-FDG PET/CT for axillary lymph node staging in patients with breast cancer. <i>Japanese Journal of Radiology</i> , 2016, 34, 220-228.	2.4	14
88	A-kinase anchoring protein BIG3 coordinates oestrogen signalling in breast cancer cells. <i>Nature Communications</i> , 2017, 8, 15427.	12.8	14
89	Harmonized pretreatment quantitative volume-based FDG-PET/CT parameters for prognosis of stage I-III breast cancer: Multicenter study. <i>Oncotarget</i> , 2021, 12, 95-105.	1.8	14
90	Prediction of hormone sensitivity for breast cancers. <i>Breast Cancer</i> , 2010, 17, 86-91.	2.9	13

#	ARTICLE	IF	CITATIONS
91	Topoisomerase IIalpha-positive and BRCA1-negative phenotype: Association with favorable response to epirubicin-based regimens for human breast cancers. <i>Cancer Letters</i> , 2008, 264, 44-53.	7.2	12
92	Improved prognosis of low baseline neutrophil-to-lymphocyte ratio is significantly exclusive in breast cancer patients with high absolute counts of lymphocytes. <i>Molecular and Clinical Oncology</i> , 2018, 10, 275-284.	1.0	12
93	Tumor mutation burden in triple negative breast cancer patients in Japan.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13111-e13111.	1.6	12
94	Prognostic significance of intra-tumoral estradiol level in breast cancer patients. <i>Cancer Letters</i> , 2004, 216, 115-121.	7.2	11
95	Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 561-567.	2.5	11
96	Involvement of B3GALNT2 overexpression in the cell growth of breast cancer. <i>International Journal of Oncology</i> , 2014, 44, 427-434.	3.3	11
97	Therapeutic advances in <sc>BIG</sc>3&#x2013;<sc>PHB</sc>2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer. <i>Cancer Science</i> , 2015, 106, 550-558.	3.9	11
98	Stapled BIG3 helical peptide ERAP potentiates anti-tumour activity for breast cancer therapeutics. <i>Scientific Reports</i> , 2017, 7, 1821.	3.3	11
99	Association Between FOXP3/CD8 Lymphocyte Ratios and Tumor Infiltrating Lymphocyte Levels in Different Breast Cancer Subtypes. <i>Anticancer Research</i> , 2020, 40, 2141-2150.	1.1	11
100	Association of body mass index with risk of luminal A but not luminal B estrogen receptor-positive and HER2-negative breast cancer for postmenopausal Japanese women. <i>Breast Cancer</i> , 2015, 22, 399-405.	2.9	10
101	C-Reactive Protein and Absolute Lymphocyte Count Can Predict Overall Survival of Patients Treated With Eribulin. <i>Anticancer Research</i> , 2020, 40, 4147-4156.	1.1	10
102	Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. <i>Breast Cancer</i> , 2021, 28, 1038-1050.	2.9	10
103	Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers. <i>Breast Cancer</i> , 2014, 21, 52-57.	2.9	9
104	Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers. <i>Breast Cancer</i> , 2016, 23, 224-230.	2.9	9
105	The GALNT6&#x2013;LGALS3BP axis promotes breast cancer cell growth. <i>International Journal of Oncology</i> , 2020, 56, 581-595.	3.3	9
106	Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases. <i>Breast Cancer</i> , 2017, 24, 245-253.	2.9	8
107	Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC). <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 755-762.	2.3	8
108	Frequent downregulation of LRRC26 by epigenetic alterations is involved in the malignant progression of triple-negative breast cancer. <i>International Journal of Oncology</i> , 2018, 52, 1539-1558.	3.3	8

#	ARTICLE	IF	CITATIONS
109	A Single-centre, Retrospective, Observational Analysis of Fulvestrant for Recurrent/metastatic Breast Cancer According to Metastatic Site. <i>Anticancer Research</i> , 2019, 39, 5653-5662.	1.1	8
110	HERC2 inactivation abrogates nucleolar localization of RecQ helicases BLM and WRN. <i>Scientific Reports</i> , 2021, 11, 360.	3.3	8
111	C-reactive Protein Level on Postoperative Day One is Associated with Chronic Postsurgical Pain After Mastectomy. <i>Anesthesiology and Pain Medicine</i> , 2018, 8, e79331.	1.3	8
112	C4.4A highly expressed in HER2-positive human breast cancers may indicate a good prognosis. <i>Breast Cancer</i> , 2015, 22, 366-373.	2.9	7
113	High levels at baseline of serum pyridinoline crosslinked carboxyterminal telopeptide of type I collagen are associated with worse prognosis for breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 521-531.	2.5	6
114	Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan. <i>Breast Cancer</i> , 2021, 28, 945-955.	2.9	6
115	Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18F-deoxyglucose levels on positron emission tomography for breast cancers. <i>PLoS ONE</i> , 2017, 12, e0184508.	2.5	6
116	Current status of endocrine therapy for breast cancer. <i>Breast Cancer</i> , 2003, 10, 105-111.	2.9	5
117	Breast cancer risk assessment for possible tailored screening for Japanese women. <i>Breast Cancer</i> , 2009, 16, 243-247.	2.9	5
118	High levels of serum CA15â€³ and residual invasive tumor size are associated with poor prognosis for breast cancer patients with nonâ€³pathological complete response after neoadjuvant chemotherapy. <i>Journal of Surgical Oncology</i> , 2018, 118, 228-237.	1.7	4
119	Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 631-635.	2.5	4
120	Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. <i>Breast Cancer</i> , 2017, 24, 528-534.	2.9	3
121	Actionable Gene Alterations in an Asian Population With Triple-Negative Breast Cancer. <i>JCO Precision Oncology</i> , 2018, 2, 1-13.	3.0	3
122	Phase I clinical trial of multi-antigen peptide vaccines therapy using cancer-testis antigens for patients with advanced or recurrent breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13037-e13037.	1.6	3
123	Prognostic value of F-FDG PET/CT prior to breast cancer treatment. Comparison with magnetic resonance spectroscopy and diffusion weighted imaging. <i>Hellenic Journal of Nuclear Medicine</i> , 2019, 22, 25-35.	0.3	3
124	Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer. <i>Anticancer Research</i> , 2014, 34, 3583-8.	1.1	2
125	Class I HDAC inhibitors inhibit the retention of BRCA1 and 53BP1 at the site of DNA damage.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13552-e13552.	1.6	1
126	Abstract 5315: Frequent downregulation of <i>SALL3</i> by recurrent genetic and epigenetic alterations is involved in triple-negative breast cancers. <i>Cancer Research</i> , 2018, 78, 5315-5315.	0.9	1



#	ARTICLE	IF	CITATIONS
127	Low intratumoral genetic neutrophil-to-lymphocyte ratio (NLR) is associated with favorable tumor immune microenvironment and with survival in triple negative breast cancer (TNBC). American Journal of Cancer Research, 2021, 11, 5743-5755.	1.4	1
128	Strategy for treatment of isolated contralateral supraclavicular recurrence in patient with breast cancer after sentinel lymph node biopsy without axillary lymph node dissection. International Cancer Conference Journal, 2014, 3, 133-139.	0.5	0
129	Investigation of a Novel S-1 Administration Schedule for Treating Metastatic and Recurrent Breast Cancer (KBCOG13). Anticancer Research, 2021, 41, 3121-3126.	1.1	0
130	Breast cancer diffuse liver metastasis with high liver stiffness using ultrasound elastography. Acta Hepatologica Japonica, 2021, 62, 647-655.	0.1	0
131	Effect of body mass index and menopausal disorders during menopause on vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: A prospective multicenter cohort study of patient-reported outcomes.. Journal of Clinical Oncology, 2014, 32, 9619-9619.	1.6	0
132	Abstract P5-09-05: Prediction of bone metastases of breast cancer using combined markers of bone metabolism and inflammation. , 2015, , .		0
133	Abstract P1-12-04: Factors influencing on discontinuation of adjuvant anastrozole in postmenopausal Japanese breast cancer patients: Results from a prospective multicenter cohort study of patient-reported outcomes. , 2015, , .		0
134	Overall survival of participants compared to non-participants in a randomized-controlled trial (SELECT BC): A prospective cohort study.. Journal of Clinical Oncology, 2016, 34, 2527-2527.	1.6	0
135	Abundant options to avoid toxicity and alternative strategies for human epidermal growth factor receptor 2-positive and hormone receptor-positive advanced breast cancer. Translational Cancer Research, 2018, 7, S514-S518.	1.0	0
136	A claims data analysis of single institution for comorbidity among various types of cancer.. Journal of Clinical Oncology, 2018, 36, e18843-e18843.	1.6	0
137	Abstract 1837: Overcoming trastuzumab resistance in HER2-overexpressing breast cancer by utilizing PHB2, a tumor suppressor of multiple resistance pathways. , 2018, , .		0
138	Abstract 5313: Frequent downregulation of SALL3 by genetic and epigenetic alterations is involved in progression and chemoresistance of triple negative breast cancers. , 2019, , .		0
139	Abstract P4-07-26: Clinical impact of tumor infiltrating lymphocytes and neutrophil-lymphocyte ratio in estrogen receptor-positive/HER2-negative breast cancer patients with high 21-gene signature recurrence scores. Cancer Research, 2022, 82, P4-07-26-P4-07-26.	0.9	0
140	Abstract 3813: PHB2 inactivation by AKAP-BIG3 is required for progression of HER2-overexpressing breast cancer. , 2019, , .		0